Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: otelixizumab, ertumaxomab, blinatumomab +19 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 6 pathways; mostly dopamine synapse | 1.00 |
Knock down and overexpress CD3E in a dopamine neuron, astrocyte and microglia tri-culture; measure evoked dopamine release and dopamine transporter uptake and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- evoked dopamine release and dopamine transporter uptake
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves evoked dopamine release by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of CD3E in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: evoked dopamine release and dopamine transporter uptake; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- CD3E in dopamine neurons, braak-0.04 (p 0.928) → -0.20 (p 0.613)receipt 10136
Swarm cases
receipt 10136: CD3E in dopamine neurons, braak
- power
- full sample -0.13 (p 0.609, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.12 (p 0.627, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.603, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to -0.02, sign flips 0; without severely affected donors -0.13 (p 0.609, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD3E in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts